AAMDSIF sponsors live education events throughout the year. This includes satellite symposia at annual medical association meetings, as well as smaller live regional events where community-based health professionals can hear from leading experts. The International Bone Marrow Failure Disease Scientific Symposium is our biennial professional meeting held near Washington, DC.
Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies
CME-certified Satellite Lunch Symposium, preceding the 61st ASH Annual Meeting
Friday, December 6, 2019 | 12:00pm - 4:00pm | Orange County Convention Center - Room W308, Orlando, FL
Plan to attend this complimentary lunch symposium that provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, AML, and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations. The program brings leaders in disease research and clinical practice together to explore solutions to improve the care of patients.
AAMDSIF and The Cleveland Clinic Foundation Center for Continuing Education acknowledge educational grants for partial support of this activity from: Celgene Corporation, Geron Corporation, Jazz Therapeutics, Onconova Therapeutics, Inc., and Takeda
2019 Bone Marrow Failure and Myeloid Neoplasms Symposia: Advances in Diagnosis and Treatment
Saturday, November 16, 2019 | 8:00 am - 2:30 pm | Mayo Clinic Center Florida - Kinne Auditorium, Jacksonville, FL
This one day program, jointly provided by Mayo Clinic, will provide updates on the most recent research related to biology and clinical management of bone marrow failure diseases including myelodysplastic syndromes (MDS), aplastic anemia (AA), paroxysmal nocturnal hemoglobinuria (PNH), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). The overall goal of this continuing education activity is to facilitate the translation of research findings into clinical practice and to improve the care of these patient populations.
Lymphoma & Myeloma Congress
October 23-26, 2019
Sheraton New York Times Square Hotel
New York, NY
The Lymphoma & Myeloma Congress, an international conference on hematologic malignancies, will be taking place October 23-26 in New York City. This 1,000+ person meeting is meant for all healthcare professionals interested in the treatment of different blood cancers. Now in its 19th year, the Lymphoma & Myeloma Congress is recognized around the world as the most respected forum for industry-leading hematologic research.
New for this year, the meeting has added a fellows workshop, designed with the educational needs of physicians-in-training in mind. Concurrent Nurse Practitioner and Physician Assistant sessions (in addition to all other regularly scheduled courses) will take place October 24-26. For more information, visit www.lymphomaandmyeloma.com. Use code “LM75” at checkout for a $75 registration discount.
NCI Myelodysplastic Syndromes Symposium at NIH
The purpose of the symposium is to bring together and inform the academic and community hospital clinicians about the latest clinical and translational research in myelodysplastic syndromes and secondary AML currently taking place at the NCI CCR and the NIH intramural research programs.
Registration and Agenda
The agenda will cover the following objectives:
- Understanding the biology of MDS and update on the currently emerging therapies for this disease
- Update the attendees with the preclinical and translational research currently ongoing at the NIH intramural programs
- Familiarize attendees with clinical trials available or being planned at the NCI CCR and the NIH Clinical Center for refractory or relapsed MDS or AML
The symposium will include speakers from the NIH intramural research programs and keynote speaker Alan List, M.D., President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Steven Pavletic, M.D., Head, Graft-versus-Host and Late Effects Section, Immune Deficiency and Cell Therapy Program, CCR, NCI
Naoko Takebe, M.D., Ph.D., Associate Chief Developmental Therapeutics Clinic, Early Clinical Trials Development Program, DCTD, NCI
Sabrina Khan, M.D., M.Ph., Clinical Fellow, Developmental Therapeutics Clinic, DCTD, NCI
BMT and Immunotherapies for Pediatric Leukemia
Current and novel treatments and financial implications
Jointly planned by the National Marrow Donor Program®/Be The Match® and the Aplastic Anemia and MDS International Foundation.
Bone marrow transplant (BMT) and immunotherapies continue to quickly evolve for pediatric leukemia, varying in the pathophysiology and management. For health professionals, knowledge of these treatment options and potential toxicities is necessary to manage and provide patients with safe and effective evidence-based care. When choosing these treatment options, families can face additional financial decisions and need assistance to manage the financial implications.
View program slides here!
ONS 2019 Satellite Symposium Enduring Program
This program was recorded at the ONS 44th Annual Congress in Anaheim, California on April 10, 2019. Topics include the latest developments in diagnosing and treating myeloid malignancies; emerging treatment options for low-risk MDS, high-risk MDS, AML, and MDS/MPN overlap; disease management for chronic anemia, side effects and treatment adherence; psychosocial considerations and palliative care to improve the quality of life for this patient population. Case studies are used to illustrate treatment decision-making and therapeutic challenges.
- Explain the role of genetic testing in diagnosing, stratifying and treating myeloid malignancies;
- Identify emerging treatment options for patients with low-risk MDS, high-risk MDS, secondary AML, and MDS/MPN overlap;
- Analyze the nurse's role in managing treatment for myeloid malignancies based on clinical presentations, diagnostic workups, transfusion dependence, and comorbidities;
- Discuss the nurse's role in collaboration with other disciplines in addressing treatment goals and providing patient education to improve outcomes.
Nancy Corbitt, BSN, RN, OCN, CRNI, University of Maryland Greenebaum Cancer Center, Baltimore, MD
- Tiffany Tanaka, MD, Division of Regenerative Medicine, UC San Diego Moores Cancer Center, San Diego, CA
- Costandina Herbert, BSN, RN, Seattle Cancer Care Alliance, Seattle, WA
- Chris Onderdonk, LCSW, Doris A. Howell Palliative Care Service, UC San Diego Hillcrest Hospital, San Diego, CA
This activity is jointly provided by Medical Learning Institute, Inc. and the Aplastic Anemia and MDS International Foundation
Commercial Support Acknowledgement
This activity is supported by an educational grant from Celgene Corporation
This activity was developed for nurses and nurse practitioners who are involved in the treatment or management of patients with bone marrow failure disease
Nursing Education Purpose Statement
The purpose of this activity is to improve the knowledge and competence of nurses concerning the treatment or management of patients with bone marrow failure disease
Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.
Nurse Practitioner Credit Designation
This activity is approved for 1.5 contact hour(s) of continuing education (which includes 0.33 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 19063760. This activity was planned in accordance with AANP Accreditation Standards and Policies.
ASH 2018 Satellite Symposium
Riding the Wave: Clinical Management of Myeloid Malignancies In an Era of Novel Therapies
Satellite Symposium organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation, preceding the 60th ASH Annual Meeting.
This CME certified activity provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, PHN, AML and myeloid malignancies. This program brings together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.